pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Under the agreement Valneva could receive up to $308 million in cash payments, after Pfizer paid $130 million up front for marketing rights to the vaccine if it succeeds in the clinic.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Pharmaceutical Technology

OCTOBER 28, 2022

According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 VAX-24 has forecasted sales of $21 million in the same year. Further plans in the making.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

JULY 2, 2021

Under the terms of the new deal, Nestle’s Health Sciences unit will pay Seres another $125 million if the FDA approves the drug – called SER-109 – and is also line for up to $225 million in commercial milestones tied to sales targets. Nestle and Seres have been working together on the microbiome project since 2016, focusing on C.

Bacterium 69

Bacterium Drugs Bacteria FDA Approval 69

XTalks

APRIL 17, 2023

The outbreak was caused by the bacterium Listeria monocytogenes , which was found in several samples of Blue Bell ice cream products, as well as in the company’s manufacturing facilities. The outbreak had a significant impact on the spinach industry, with an estimated loss of $74 million in sales.

Contamination 98

Contamination Bacterium Production Regulation 98

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. billion in sales in 2020 and has been outselling Merck’s previous shot, Pneumovax 23, by almost five to one. This is seven more strains than its current winning vaccine Prevnar 13, which registered $5.95

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

pharmaphorum

MARCH 2, 2022

diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections. PF-06425090 has been held up as one of the top prospects in Pfizer’s pipeline, with blockbuster sales potential. With no approved vaccines to date, C.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

Pharma in Brief

NOVEMBER 20, 2023

Instead, the Natural Health Products Regulations ( NHP Regulations ) govern the sale, manufacture, packaging, labelling, importation, distribution, and storage of natural health products. In its August 16, 2023 decision in Le-Vel Brands, LLC v.

Production 52

Production Cosmetics Regulation Branding 52